Sourcing Disclosure: Licensed Bangladesh Global Sourcing Specialist facilitating global access under Named Patient Regulations. Expert-reviewed clinical data for prescription-only medicine.

Salma Abdel, Evidence-Based Medical Researcher

Healthcare professional with over 13 years of experience in hospital and healthcare administration environments. Skilled in Quality Management System Implementation , ISO 9001 and ISO 45001 compliance, Internal Auditing, Risk assessment, CAPA management, KPI monitoring, Oncology Product analysis and Product Leaflet writing.

Joined: March 1, 2026
Articles: 17

HR+ Breast Cancer, HER2-Negative (HER2-), PIK3CA, AKT1, or PTEN Alteration

AKT Mutation Alterations in Oncology: Molecular Drivers and Targeted Inhibitor Protocols

Schematic-diagram-of-PI3K-Akt-mTOR-pathway-AKT Mutation

Educational Overview Receiving an advanced cancer diagnosis immediately necessitates a transition from generalized anatomical staging to precise molecular profiling. In modern oncology, the standard of care dictates that malignancies are treated based on their specific genetic drivers. Among the most…

Salma Abdel, Evidence-Based Medical Researcher
March 14, 2026

Blog, Acute Myeloid Leukemia Treatment, Precision Oncology

Clinical Guide to the FLT3 Mutation in Acute Myeloid Leukemia (AML)

Table of Content A primary diagnosis of Acute Myeloid Leukemia (AML) introduces patients and their families to a highly complex landscape of hematology, molecular biology, and genomic profiling. Modern precision oncology no longer relies solely on identifying the morphological type…

Salma Abdel, Evidence-Based Medical Researcher
March 14, 2026

Non-small Cell Lung Cancer Targeted Therapy, Blog

Clinical Guide to the BRAF Mutation and Targeted Therapy

Understanding your pathology report and genetic testing is the first step in precision oncology. If your tumor tissue has tested positive for a BRAF mutation, your medical team has identified the specific genetic driver responsible for your cancer’s growth. This…

Salma Abdel, Evidence-Based Medical Researcher
March 14, 2026

Blog, Non-small Cell Lung Cancer Targeted Therapy

ROS1 Gene Fusions in NSCLC: Targeted Therapies and Clinical Management

Receiving a cancer diagnosis immediately thrusts you into a complex world of medical terminology, cellular biology, and genetic testing. Today, oncology relies heavily on understanding the unique genetic blueprint of a tumor. Instead of categorizing cancer solely by where it…

Salma Abdel, Evidence-Based Medical Researcher
March 12, 2026

Blog

KRAS G12C Mutation in Advanced NSCLC: Targeted Therapies and Clinical Management

KRAS G12C Mutation involvement in non-small cell lung cancer. The Diagram shows the historical data of this mutation.

A cancer diagnosis often introduces a completely new vocabulary. You might hear your oncology team discuss genes, mutations, and targeted therapies. In modern oncology, treating cancer requires understanding the specific genetic blueprint of the tumor. One of the most significant…

Salma Abdel, Evidence-Based Medical Researcher
March 12, 2026

Blog

NSCLC Targeted Therapies: Biomarker Profiling and Precision Oncology Protocols

How Receptor Tyrosine kinase inhibitor works in non-small cell lung cancer

Introduction: The Shift to Precision Medicine Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for roughly 80% to 85% of all lung cancer diagnoses. For decades, the standard approach to treating NSCLC relied heavily…

Salma Abdel, Evidence-Based Medical Researcher
March 12, 2026

Blog, HR+ Breast Cancer

PIK3CA Mutations in HR+ Breast Cancer: Targeted Therapies and Metabolic Management

If you have been told you have a PIK3CA mutation, you are likely dealing with Hormone Receptor-positive (HR+), HER2-negative metastatic breast cancer. This blog is designed to pull back the curtain on the science, explain the research, and help you…